Company
Hunazine Biotech, a drug development company focused exclusively on IBD, secured an exclusive global license1 for a new and patented molecule VR-AD-10112, which is a breakthrough treatment candidate for symptoms of IBD. BT endeavors to leverage its expertise in clinical development to ensure quick commercial success for VR-AD-1011 and BT.
Product – VR-AD-1005
Hunazine Biotech, acquired an exclusive global license for IBD from Vanessa Biotech (VB), a leading research company in the development of novel anti-diarrheal products3. VB products demonstrated therapeutic efficacy in the treatment of diarrhea, which was labeled as untreatable by medical experts (MVID) 4. VB’s unique products ensure competitive edge in highly lucrative market.
Development Phase
Currently, Hunazine Biotech is currently conducting Phase II clinical trials in Bangladesh and Ghana . Expected time to Phase II completion and beginning of Phase III is 2024.
